| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Across the recent three months, 14 analysts have shared their insights on Intra-Cellular Therapies (NASDAQ:ITCI), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 9 | 4 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 8 | 2 | 1 | 0 | 0 |
| 3M Ago | 1 | 1 | 0 | 0 | 0 |
The 12-month price targets, analyzed by analysts, offer insights with an average target of $91.57, a high estimate of $120.00, and a low estimate of $77.00. This upward trend is apparent, with the current average reflecting a 10.19% increase from the previous average price target of $83.10.
The analysis of recent analyst actions sheds light on the perception of Intra-Cellular Therapies by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jessica Fye | JP Morgan | Raises | Overweight | $78.00 | $75.00 |
| Ami Fadia | Needham | Maintains | Buy | $90.00 | $90.00 |
| Ami Fadia | Needham | Maintains | Buy | $90.00 | $90.00 |
| Charles Duncan | Cantor Fitzgerald | Maintains | Overweight | $120.00 | - |
| Sumant Kulkarni | Canaccord Genuity | Raises | Buy | $107.00 | $100.00 |
| Ami Fadia | Needham | Raises | Buy | $90.00 | $82.00 |
| Graig Suvannavejh | Mizuho | Raises | Buy | $96.00 | $82.00 |
| Corinne Jenkins | Goldman Sachs | Raises | Neutral | $77.00 | $67.00 |
| Jason Gerberry | B of A Securities | Raises | Buy | $91.00 | $82.00 |
| Joel Beatty | Baird | Raises | Outperform | $103.00 | $83.00 |
| Joseph Thome | TD Cowen | Raises | Buy | $90.00 | $80.00 |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Ami Fadia | Needham | Maintains | Buy | $82.00 | - |
| Brian Abrahams | RBC Capital | Maintains | Outperform | $86.00 | - |
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Intra-Cellular Therapies's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
Stay up to date on Intra-Cellular Therapies analyst ratings.
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Intra-Cellular Therapies's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 52.9% as of 31 March, 2024, showcasing a substantial increase in top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -10.53%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Intra-Cellular Therapies's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -2.56%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -2.07%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of 0.03, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: ITCI
